Emerging oligonucleotide therapeutics for rare neuromuscular diseases
Research and drug development concerning rare diseases are at the cutting edge of scientific technology. To date, over 7,000 rare diseases have been identified. Despite their individual rarity, 1 in 10 individuals worldwide is affected by a rare condition. For the majority of these diseases, there i...
Asıl Yazarlar: | Aoki, Y, Wood, MJA |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
IOS Press
2021
|
Benzer Materyaller
-
Oligonucleotide-based therapies for neuromuscular disease
Yazar:: Douglas, A, ve diğerleri
Baskı/Yayın Bilgisi: (2015) -
Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
Yazar:: Tsoumpra, MK, ve diğerleri
Baskı/Yayın Bilgisi: (2019) -
Advances in oligonucleotide drug delivery
Yazar:: Roberts, TC, ve diğerleri
Baskı/Yayın Bilgisi: (2020) -
Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases
Yazar:: Ashok Verma
Baskı/Yayın Bilgisi: (2018-01-01) -
Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
Yazar:: Gait, M, ve diğerleri
Baskı/Yayın Bilgisi: (2018)